XW0433AIntroduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10

New Technology›Anatomical Regions›Introduction

Billable / Specific Code

ICD-10-PCS XW0433A

CMS Source: FY 2026 ICD-10-PCS dataset. Effective Oct 1, 2025 – Sep 30, 2026.

XW0433A is a billable ICD-10-PCS procedure code for Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

Code Identity

ICD-10-PCS Code

XW0433A

Billable Status

Yes — Valid for Submission

Code Describes

Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10

Parent Code

XW0

Short Description

Introduce Bentracimab in Central Vein, Perc, New Tech 10

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

Position	Designation	Value	Meaning
1	Section	X	New Technology
2	Body System	W	Anatomical Regions
3	Operation	0	Introduction
4	BodyPart	4	Central Vein
5	Approach	3	Percutaneous
6	Device/Substance/Technology	3	Bentracimab, Ticagrelor Reversal Agent
7	Qualifier	A	New Technology Group 10

Code History

Replaces previously assigned code(s):

3E043GC — Introduce Oth Therap Subst in Central Vein, Perc

Similar Procedure Codes

Filter related codes list:

Questions About XW0433A

Is XW0433A a billable code?

Yes. XW0433A is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10 on inpatient claims from October 1, 2025 through September 30, 2026.

What do the characters in XW0433A mean?

XW0433A breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character 3 is the Device/Substance/Technology (Bentracimab, Ticagrelor Reversal Agent); the 7th character A is the Qualifier (New Technology Group 10).